GlassScriptPhysician profile
Lacey Rose Young
NPI 1932728300
$1,773.93
in general payments reported to CMS, 2019-2025
22 companies · $881 in 2025
The $881 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $96.08 · 2023: $40.79 · 2024: $756 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.90 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.84 | 2024-2025 | |
| Medtronic, INC. | $216.55 | 2022-2025 | Inceptiv |
| Otsuka America Pharmaceutical, INC. | $108.54 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $102.22 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $101.55 | 2024-2025 | Farxiga |
| Astellas Pharma US INC | $98.88 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.58 | 2023-2025 | Xifaxan |
| Eisai INC. | $94.29 | 2024 | |
| Novo Nordisk INC | $81.44 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $77.94 | 2024-2025 | Voquezna |
| Amgen INC. | $77.22 | 2024-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $74.57 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $45.71 | 2024-2025 | |
| Genzyme Corporation | $41.60 | 2024 | |
| Merck Sharp & Dohme LLC | $32.33 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.06 | 2025 | Caplyta |
| Seqirus USA INC | $20.23 | 2024 | Flucelvax |
| Sumitomo Pharma America, INC. | $18.57 | 2025 | Gemtesa |
| Exact Sciences Corporation | $16.80 | 2024 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $16.67 | 2025 | |
| Pfizer INC. | $13.84 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.